Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexordexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) Meeting Abstract

  

Authors:	Bahlis, N. J.; Usmani, S. Z.; Rosiñol, L.; Krishnan, A. Y.; Nooka, A. K.; Rocafiguera, A. O.; Delforge, M.; Garfall, A. L.; van De Donk, N. W. C. J.; Rodríguez-Otero, P.; Martin, T. G.; Diels, J.; Van Sanden, S.; Pei, L.; Ammann, E.; Kobos, R.; Slavcev, M.; Smit, J.; Londhe, A.; Moreau, P.
Abstract Title:	Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexordexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Meeting Title:	2022 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	40
Issue:	16 Suppl.
Meeting Dates:	2022 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2022-06-01
Language:	English
ACCESSION:	WOS:000863680304138
PROVIDER:	wos
DOI:	10.1200/JCO.2022.40.16_suppl.e20028
Notes:	Meeting Abstract: e20028 -- This meeting was also held virtually -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/201298